Need more? Try out  Advanced Search (20+ criteria)»

Last Update

is this you? Claim your profile.

Wrong Michael Haude?

Michael Haude

Chief of Cardiology

Lukaskrankenhaus

GET ZOOMINFO GROW

+ Get 10 Free Contacts a Month

Please agree to the terms and conditions.

I agree to the  Terms of Service and  Privacy Policy. I understand that I will receive a subscription to ZoomInfo Grow at no charge in exchange for downloading and installing the ZoomInfo Contact Contributor utility which, among other features, involves sharing my business contacts as well as headers and signature blocks from emails that I receive.

THANK YOU FOR DOWNLOADING!

computers
  • 1.Download
    ZoomInfo Grow
    v sign
  • 2.Run Installation
    Wizard
  • 3.Check your inbox to
    Sign in to ZoomInfo Grow

I agree to the Terms of Service and Privacy Policy. I understand that I will receive a subscription to ZoomInfo Community Edition at no charge in exchange for downloading and installing the ZoomInfo Contact Contributor utility which, among other features, involves sharing my business contacts as well as headers and signature blocks from emails that I receive.

Lukaskrankenhaus

Find other employees at this company (9)

Web References(62 Total References)


www.dicardiology.com

Michael Haude, M.D., of the Lukaskrankenhaus, Neuss, Germany, principal investigator of the study, commented:


www.dicardiology.com

"The results of BIOSOLVE-II confirm that the Biotronik Magnesium Scaffold is both a safe and effective option for treating coronary artery disease (CAD), and establish it as the first clinically-proven magnesium-based bioresorbable scaffold," commented principal investigator of the study Michael Haude, M.D., of the Lukaskrankenhaus, Neuss, Germany.
It is based on a natural element widely present in the human body, and the magnesium-based properties promote a faster and simpler implantation procedure," commented Haude.


www.crf.org [cached]

Michael Haude, MD, PhD
Lukaskrankenhaus Neuss


citoday.com

Concurrent with the presentation, the positive data from BIOSOLVE-II supporting the device's safety and clinical performance were published by Principal Investigator Prof. Michael Haude, MD, et al online in The Lancet.
In May 2016, the company announced that 1-year data confirming long-term safety from the BIOSOLVE-II trial were presented by Prof. Haude at the EuroPCR 2016 conference and concurrently published online by Prof. Haude, et al in the European Heart Journal. In the company's press release, Prof. Haude commented, "Now that clinical results have firmly established the safety and clinical performance of Magmaris, the magnesium-based scaffold could emerge as a strong alternative to currently available polymer-based scaffolds. Because it is made of magnesium, the scaffold has some unique advantages over polymer-based options in terms of deliverability and radial resistance following the implantation procedure. Prof. Haude is with Lukaskrankenhaus in Neuss, Germany.


citoday.com

May 19, 2016-One-year data from the BIOSOLVE-II trial of Biotronik's Magmaris magnesium-based, sirolimus-eluting bioresorbable scaffold were presented by Principal Investigator Prof. Michael Haude, MD, at the EuroPCR 2016 conference held May 17-20 in Paris, France.
The data were concurrently published online by Prof. Haude et al in The European Heart Journal. According to Biotronik, the study established the safety and clinical performance of the Magmaris device. Dr. Haude commented in the company's press release, "These results offer the first confirmation of Magmaris' longer-term safety and efficacy. BIOSOLVE-II demonstrates a promising potential of a magnesium-based approach to treating coronary artery disease as an alternative to polymer-based bioresorbable scaffolds. Dr. Haude is with the Lukaskrankenhaus in Neuss, Germany.


Similar Profiles

city

Browse ZoomInfo's Business
Contact Directory by City

city

Browse ZoomInfo's
Business People Directory

city

Browse ZoomInfo's
Advanced Company Directory